The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Effective Treatment With Oral Sulfonylureas in Patients With Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations
Open accessAbstract
OBJECTIVE—Neonatal diabetes can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K+ channel. Transfer from insulin to oral sulfonylureas in patients with neonatal diabetes due to Kir6.2 mutations is well described, but less is known about changing therapy in patients with SUR1 mutations. We aimed to describe the response to sulfonylurea therapy in patients with SUR1 mutations and to compare it with Kir6.2 mutations. RESEARCH DESIGN AND METHODS—We followed 27 patients with SUR1 mutations for at least 2 months after attempted transfer to sulfonylureas. Information was collected on clinical features, treatment before and after transfer, and the transfer protocol used. We compared successful and unsuccessful transfer patients, glycemic control before and after transfer, and treatment requirements in patients with SUR1 and Kir6.2 mutations. RESULTS—Twenty-three patients (85%) successfully transferred onto sulfonylureas without significant side effects or increased hypoglycemia and did not need insulin injections. In these patients, median A1C fell from 7.2% (interquartile range 6.6–8.2%) on insulin to 5.5% (5.3–6.2%) on sulfonylureas (P = 0.01). When compared with Kir6.2 patients, SUR1 patients needed lower doses of both insulin before transfer (0.4 vs. 0.7 units · kg−1 · day−1; P = 0.002) and sulfonylureas after transfer (0.26 vs. 0.45 mg · kg−1 · day−1; P = 0.005). CONCLUSIONS—Oral sulfonylurea therapy is safe and effective in the short term in most patients with diabetes due to SUR1 mutations and may successfully replace treatment with insulin injections. A different treatment protocol needs to be developed for this group because they require lower doses of sulfonylureas than required by Kir6.2 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Self-citationSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988
Self-citationTruncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor
Tucker, S. J., Gribble, F. M., Zhao, C., Trapp, S., & Ashcroft, F. M. (1997) · Nature · doi:10.1038/387179a0 · Cited by 753
Activating Mutations in the ABCC8 Gene in Neonatal Diabetes Mellitus
Babenko, A. P., Polak, M., Cavé, H., Busiah, K., Czernichow, P., Scharfmann, R., Bryan, J., Aguilar-Bryan, L., Vaxillaire, M., & Froguel, P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055068 · Cited by 655
Flanagan, S. E., Patch, A.-M., Mackay, D. J. G., Edghill, E. L., Gloyn, A. L., Robinson, D., Shield, J. P. H., Temple, K., Ellard, S., & Hattersley, A. T. (2007) · Diabetes · doi:10.2337/db07-0043 · Cited by 357
Self-citationProks, P., Antcliff, J. F., Lippiat, J., Gloyn, A. L., Hattersley, A. T., & Ashcroft, F. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404756101 · Cited by 234
Self-citationFlanagan, S. E., Edghill, E. L., Gloyn, A. L., Ellard, S., & Hattersley, A. T. (2006) · Diabetologia · doi:10.1007/s00125-006-0246-z · Cited by 227
Self-citationEllard, S., Flanagan, S. E., Girard, C. A., Patch, A.-M., Harries, L. W., Parrish, A., Edghill, E. L., Mackay, D. J. G., Proks, P., Shimomura, K., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519174 · Cited by 215
Self-citationProks, P., Arnold, A. L., Bruining, J., Girard, C., Flanagan, S. E., Larkin, B., Colclough, K., Hattersley, A. T., Ashcroft, F. M., & Ellard, S. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl101 · Cited by 211
Self-citationVaxillaire, M., Populaire, C., Busiah, K., Cavé, H., Gloyn, A. L., Hattersley, A. T., Czernichow, P., Froguel, P., & Polak, M. (2004) · Diabetes · doi:10.2337/diabetes.53.10.2719 · Cited by 186
Self-citationMolecular Analysis of ATP-sensitive K Channel Gating and Implications for Channel Inhibition by ATP
Trapp, S., Proks, P., Tucker, S. J., & Ashcroft, F. M. (1998) · The Journal of General Physiology · doi:10.1085/jgp.112.3.333 · Cited by 170 · cited 7×
“This can be explained by in vitro studies that found that mutations associated with neurological symptoms are less responsive to sulfonylureas as well as responding less to ATP (19,20).”
InfluentialMassa, O., Iafusco, D., D’Amato, E., Gloyn, A. L., Hattersley, A. T., Pasquino, B., Tonini, G., Dammacco, F., Zanette, G., Meschi, F., et al. (2004) · Human Mutation · doi:10.1002/humu.20124 · Cited by 151
Self-citationStaník, J., Gašperíková, D., Paskova, M., Barák, Ľ., Javorkova, J., Jancova, E., Čiljaková, M., Hlava, P., Michálek, J., Flanagan, S. E., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2490 · Cited by 112
Self-citationTissue-specific effects of sulfonylureas
Ashcroft, F. M., & Gribble, F. M. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00081-7 · Cited by 111
Gloyn, A. L., Siddiqui, J., & Ellard, S. (2006) · Human Mutation · doi:10.1002/humu.20292 · Cited by 111
Self-citationPatch, A., Flanagan, S. E., Boustred, C. R., Hattersley, A. T., & Ellard, S. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00772.x · Cited by 93
Self-citationNew ABCC8 Mutations in Relapsing Neonatal Diabetes and Clinical Features
Vaxillaire, M., Dechaume, A., Busiah, K., Cavé, H., Pereira, S., Scharfmann, R., de Nanclares, G. P., Castaño, L. A., Froguel, P., Polak, M., et al. (2007) · Diabetes · doi:10.2337/db06-1540 · Cited by 85
Masia, R., León, D. D. D., MacMullen, C., McKnight, H., Stanley, C. A., & Nichols, C. G. (2007) · Diabetes · doi:10.2337/db06-1746 · Cited by 49
Malecki, M. T., SKUPIEN, J. K., Klupa, T., Wanic, K., Mlynarski, W. M., Gach, A., Solecka, I., & Sieradzki, J. (2006) · Diabetes Care · doi:10.2337/dc06-1628 · Cited by 33
Sulfonylurea Treatment in Young Children With Neonatal Diabetes
Ethel Codner, D., Flanagan, S. E., Ugarte, F., García, H., Vidal, T., Ellard, S., & Hattersley, A. T. (2007) · Diabetes Care · doi:10.2337/dc06-2134 · Cited by 31
Self-citation
Cited by
Genomics, type 2 diabetes, and obesity
McCarthy, M. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906948 · Cited by 938
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Osbak, K. K., Colclough, K., Saint-Martin, C., Beer, N. L., Bellanné-Chantelot, C., Ellard, S., & Gloyn, A. L. (2009) · Human Mutation · doi:10.1002/humu.21110 · Cited by 485
Self-citationDe Franco, E., Flanagan, S. E., Houghton, J. A., Allen, H. L., Mackay, D. J., Temple, I. K., Ellard, S., & Hattersley, A. T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60098-8 · Cited by 349
Self-citationJapanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Metadata
- Authors
- Rafiq, M., Flanagan, S. E., Patch, A.-M., Shields, B. M., Ellard, S., Hattersley, A. T., & The Neonatal Diabetes International Collaborative Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-02-01
- Volume
- 31
- Issue
- 2
- Pages
- 204-209
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2113676079
- Cited by
- 265
- References
- 20
- FWCI
- 19.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.